glp-1 liver fibrosis Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Revolutionizing MASLD treatment with GLP-1
Description
But both are very effective, and many patients do great on either
These concerns kept GIP on the back burner for years while GLP-1 took center stage in drug development
Until then, patients should focus on safe, available, evidence-based care
17% with placebo
The average amount of weight gain for someone taking Zoloft is 10.5 pounds over two years
J Bone Miner Res 35:14151423 Khalid SI, Omotosho PA, Spagnoli A, Torquati A (2020) Association of bariatric surgery with risk of fracture in patients with severe obesity
